Introduction {#sec1_1}
============

Over the latest two decades the use of imaging procedures, especially ultrasonography (US) has been the culprit of an epidemic of thyroid incidentalomas \[[@B1]\]. Thus, the clinician is confronted with a situation that necessitates managing a condition that the patient did not complain of. In the first part, this paper outlines the magnitude of the problem and updates the concept of US risk stratification of thyroid nodules based on the TIRADS (thyroid imaging reporting and data system) classification. The second part deals with the indications for US fine-needle aspiration biopsy (FNA), addresses specifically the problem of subcentimetric incidentalomas and microcarcinomas, and finally discusses the potential of nonsurgical therapeutic alternatives.

Epidemiology {#sec1_2}
============

A thyroid incidentaloma is defined as an unexpected, asymptomatic thyroid tumor discovered during the investigation of an unrelated condition. Palpable thyroid nodules are known to be frequent, with a 5% prevalence rate in the general population \[[@B2],[@B3]\]. There is a female preponderance and an increase in prevalence with age, reaching 30-40% \[[@B3]\] in individuals above the age of 50. Older studies report that neck US detects incidentalomas with a prevalence of 10-30% \[[@B4],[@B5],[@B6]\]. With more recent-generation US, which offers improved spatial resolution, the prevalence is 67%, comparable to that found at autopsy \[[@B7]\]. Prospective studies in the general population have shown a very high prevalence of small thyroid nodules detectable with US, measuring \<10 mm in 70-83% of cases \[[@B5],[@B6]\]. Employing computed tomography (CT) or magnetic resonance imaging (MRI) of the neck, prevalence is lower at around 15% \[[@B8],[@B9]\], while it is 1-2% by fluorodeoxyglucose (FDG) positron emission tomography (PET) \[[@B10],[@B11]\]. Using PET, a thyroid incidentaloma is defined as a focal uptake and should be clearly differentiated from bilateral and diffuse thyroid uptake linked to thyroiditis and with a much lower risk of malignancy.

Diagnosis and exploration of thyroid incidentalomas preferentially takes place in high-income countries where imaging is increasingly used for patients who have access to medical care \[[@B12]\]. For example, in the USA, the number of CTs performed between 1995 and 2005 increased more than threefold, and the number of MRIs more than doubled \[[@B13]\]. It follows, not surprisingly, that the number of FNAs has also increased correspondingly \[[@B13]\].

Risk of Malignancy according to the Way of Discovery {#sec1_3}
====================================================

In the absence of a history of external beam radiation or familial medullary thyroid cancer, the risk of malignancy in thyroid incidentalomas diagnosed on neck US, CT or MRI is 5-13% \[[@B11],[@B14]\]. In contrast, the risk of malignancy when diagnosed by focal FDG uptake on a PET scan is much higher, around 30% \[[@B10]\]. Importantly, although the FDG PET examinations are performed in the context of another malignancy, most FDG thyroid incidentalomas detected by PET scan are differentiated thyroid cancers and not intrathyroidal metastases \[[@B10]\]. Sixty-seven percent of thyroid cancers detected by imaging measure more than 10 mm and 38% measure more than 4 cm. Twenty-five percent are stage III or IV, and 30% have positive lymph nodes \[[@B15]\].

Risk Stratification of Thyroid Incidentalomas with Ultrasound {#sec1_4}
=============================================================

Can US be used as an accessible, simple and inexpensive tool to sort the wheat from the chaff among thyroid incidentalomas? Thyroid US was first used as a tool to measure, count and locate thyroid nodules. Since around 1998, specific US characteristics have been recognized as markers of thyroid carcinoma \[[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25]\]. Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarize the reported sensitivities, specificities, and positive and negative predictive values of each of these signs.

Unfortunately, no single US sign has sufficient diagnostic value. Therefore, various combinations of signs have been studied for that purpose. Among these was a combination of four signs, first reported by Kim et al. \[[@B18]\] and then confirmed by other groups \[[@B19],[@B20]\]. These included microcalcifications, a taller-than-wide shape, irregular borders and marked hypoechogenicity, and were considered capable of diagnosing 94% of thyroid carcinomas. Mild hypoechogenicity is often added to that list \[[@B16],[@B17],[@B19],[@B22],[@B23],[@B24]\], and more recently low elasticity employing elastography \[[@B22],[@B23],[@B24]\]. At the other side of the spectrum, simple cysts and spongiform nodules have been classified as characteristic of benign lesions \[[@B25]\]. In a recent review and meta-analysis, Brito et al. \[[@B26]\] found that the US nodule features with the highest diagnostic odds ratio for malignancy was being 'taller than wider' and that spongiform appearance and cystic nodules were the best two features allowing avoidance of FNA.

In 2007, a qualitative risk assessment concept called the 'grading system' emerged. Thyroid nodules were classified into categories related to their US patterns. Indications for FNA were based on these categories \[[@B27],[@B28]\]. In 2009, risk stratification shifted to quantitative assessment, linking US patterns to a quantitative risk of malignancy. In the six main reports on this subject, the authors named their work either 'reporting systems' or 'TIRADS' which is the acronym for 'thyroid imaging-reporting and data system'.

In 2009, Horvath et al. \[[@B29]\] published the first study using TIRADS in 1,097 nodules (156 carcinomas). The grading concept is transposed in a way similar to BI-RADS (Breast Imaging-Reporting and Data System): score 1 denotes a normal examination, whereas scores 2, 3, 4 and 5 correspond to a risk of 0, \<5, 5-80 and \>80%, respectively. Ten US patterns (cumbersome to use in clinical practice) were defined. Sensitivity and specificity were 88 and 49%, respectively. However, among 1,097 nodules, 238 were classified as indeterminate/suspicious follicular lesions and only 12% were operated on, introducing a selection bias.

The same year, Park et al. \[[@B30]\], in a retrospective study, used TIRADS in a study that comprised 1,694 patients (364 carcinomas). The value of the 4 major signs of Kim et al. \[[@B18]\] was confirmed and 2 signs were added: solid and mildly hypoechoic, and the presence of suspicious lymph nodes. They established a mathematical equation with 12 parameters and a 5-point risk stratification scale. There were 390 nodules with a THY3 reading (indeterminate), and 256 were excluded from the analysis because they did not have thyroid surgery. FNA was recommended for scores 3 and 4, and surgery for score 5. The diagnostic value was not tested and, again, the process was too complex to be applied in daily practice.

In 2011, Kwak et al. \[[@B31]\] tried to simplify the system designed by Park et al. \[[@B30]\] in a multicenter retrospective study of 1,658 nodules \>10 mm, 298 of which were surgically removed. The total number of cytologically indeterminate nodules is not available, but all the ones retained in the study were referred for surgery. The number of signs of suspicion could clearly be used to predict malignancy. However, as a main limitation, each suspicious US feature was assigned the same weight despite carrying a different probability of malignancy.

In 2013, to overcome this shortcoming, Kwak et al. \[[@B32]\] suggested a new model where each individual US sign was assigned a risk score according to its odds ratio for predicting malignancy. In their multicenter study of 2,000 nodules measuring at least 5 mm, all carcinomas (36.6%) were surgically confirmed. All benign nodules were characterized by at least 2 benign FNA examinations and evidence of lack of growth over the study period. The risk of malignancy in thyroid nodules increased in parallel with the calculated total score (sum of each score). Unfortunately, and intuitively, applying this 15-point scale is far too time-consuming.

Given the above shortcomings, Russ et al. \[[@B33]\] constructed a system that is less cumbersome, reproducible and allows testing. First, a retrospective study of 500 nodules was performed. The sensitivity, specificity and odds ratio of each US sign were calculated, and a specific vocabulary and a standardized report were established. A flowchart was developed to easily define the score of a particular nodule. Sensitivity and specificity of this version of the TIRADS score were 95 and 68%, respectively. Feedback from the medical community led to simplification and subsequently a prospective study of 4,550 nodules over a 2-year period that included elastography \[[@B34]\]. There were 801 cytologically indeterminate results (17.6%), in which histological confirmation was available in 237 cases. The algorithm is shown in figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Assessment categories corresponded to a 6-point scale: score 1 is for normal, 2 for benign, 3 for very probably benign, 4A for low suspicion, 4B for high suspicion and 5 for practically certainly malignant. The corresponding risk of malignancy, using this scale, was 0, 0, 0.25, 6, 69 and 100%, respectively. Sensitivity reached 98.5%; false-negative results corresponded, in most cases, to the encapsulated follicular variant of papillary carcinomas, which occasionally takes on the US appearance of a regular solid isoechoic nodule with or without central vascularization \[[@B35],[@B36]\]. Specificity, negative predictive value and accuracy of this TIRADS score were 44.7, 99.8 and 48.3%, respectively. Nodules given a score of 2 or 3 represented 52% of all nodules referred for FNA, and 65% of all nodules detected by US. Interobserver reproducibility yielded a κ coefficient of 0.72, corresponding to substantial agreement. This figure is close to what was reported by Hambly et al. \[[@B37]\], who asked 7 radiologists to test a 5-point scale very similar to TIRADS and found that agreement was excellent for malignant nodules (κ, 0.88-1.00).

Most risk stratification systems are based on gray-scale US. Doppler US is frequently not taken into account. Its diagnostic value remains controversial, probably due to its entirely qualitative nature, poor interobserver agreement and dependence on the sensitivity of the US technology. However, predominantly central vascularization seems to increase the risk of malignancy and can be used to ascertain this risk in a more refined way \[[@B16],[@B17],[@B38]\]. Regarding US elastography, there is currently no clear superiority of one elastographic technique over another. Manual compression has the main advantage of widespread availability, but techniques based on the ultrasound radiation force, such as shear wave imaging, ought to be more reproducible. The main aim of elastography is to improve the sensitivity of gray-scale imaging, but it may also be used to enhance specificity in nodules with undetermined US patterns, such as TIRADS 4A or undetermined cytological patterns, such as follicular neoplasms \[[@B21],[@B22],[@B23],[@B24]\].

All of the studies have two main shortcomings: (1) the lack of surgical confirmation of most nodules considered as cytologically benign, and (2) the exclusion of many cytologically indeterminate nodules. However, and importantly, we now have at our disposal a tool which can detect most thyroid carcinomas and classify more than half of all nodules as very probably benign with a \<1/400 risk of missing a carcinoma \[[@B34]\]. We suggest using this tool when deciding which nodules to offer FNA and for managing the US follow-up.

Indications for US FNA in Thyroid Incidentalomas {#sec1_5}
================================================

FNA is considered the most reliable test for the diagnosis of malignant thyroid nodules. Guidance regarding the indications for US FNA in case of incidentalomas does exist, especially in case of a history of familial thyroid cancer or previous head/neck irradiation, both of which increase the risk of thyroid cancer \[[@B39]\]. The nodule size at initial US, the US risk stratification score and the increase in size during follow-up may be accepted as the most reasonable criteria for deciding whether to proceed or not to US FNA (fig. [3](#F3){ref-type="fig"}).

Subcentimetric Nodules {#sec2_1}
----------------------

As they are practically always asymptomatic, the sole question for these small nodules is what are the benefits and risks of overdiagnosis versus postponing diagnosis? Many (but far from all) thyroid incidentalomas are microcarcinomas. This helps to explain the rise in the incidence of papillary thyroid cancers, which has been observed in high-income countries for more than two decades \[[@B40]\]. However, among these, microcarcinomas fortuitously discovered after thyroidectomy for benign diseases represent 64% of all incidental microcarcinomas \[[@B41]\]. They do not correspond to the index tumor, which is primarily investigated by imaging, and should not be confused in the discussion of incidentalomas discovered with medical imaging.

The overall prognosis of papillary microcarcinomas (PTMCs) is excellent and evolution slow. The disease-specific mortality from microcarcinoma not diagnosed because of palpable lymph nodes is indeed \<1% and some authors advocate follow-up of patients with thyroid cancer of \<1 cm rather than surgery \[[@B42]\]. A wait-and-see policy is safe because the increase in size of microcarcinomas is low during follow-up. In the study by Ito et al. \[[@B43]\], which included PTMCs with a mean size of 6.9 mm, 6.4 and 15.9% of PTMCs followed up without any treatment showed increased size by 3 mm or more during a 5- and 10-year follow-up period, respectively. In the study by Sugitani et al. \[[@B44]\], which included PTMCs with a mean size of \>8 mm, 7% of PTMCs increased in size during a mean 5-year follow-up period and 1% developed apparent lymph nodes. However, not all microcarcinomas represent indolent disease. Patients with follicular and Hürthle cell microcarcinomas have a much poorer prognosis \[[@B45]\], and in a report by Noguchi et al. \[[@B46]\] the recurrence rate at 35 years of treated carcinomas between 6 and 10 mm was 14%.

Not to be forgotten, several studies have reported that the proportion of adequate cytological material is significantly lower in small nodules \[[@B47]\] (85% in supracentimetric nodules and 69% in subcentimetric nodules) \[[@B48],[@B49]\]. This was confirmed in 2009, in a report where the inadequacy rate was 20, 9 and 5% for nodules ≤5, \>5 and ≤10, and \>10 mm, respectively \[[@B50].\]

The current guidelines on subcentimetric nodules give different recommendations. The ATA \[[@B51]\] recommends FNA for nodules \>5 mm, in case of a high-risk history and if the nodule has suspicious sonographic features. The Society of Radiologists in Ultrasound \[[@B52]\] considers that there is no sufficient proof of any benefit of recommending FNA of subcentimetric nodules. Finally, in the guidelines of the AACE/AME/ETA \[[@B53]\], it is stated that suspicious lesions \<10 mm should be assessed with FNA biopsy, especially in case of a suspicious history.

For these subcentimetric nodules, we suggest that routine FNA not be recommended in most cases, that it can be considered for nodules with a TIRADS score of 5 or 4B, and that it should -- independent of the size of the nodule -- be performed systematically on suspicious lymph nodes if one exists. Future guidelines should incorporate new US criteria to better define which nodules carry a risk of harboring aggressive characteristics and therefore warrant FNA, i.e. nodules located near the thyroid capsule or suspected of extending beyond it \[[@B54],[@B55],[@B56]\]. Since the risk of being a pT3 carcinoma and association with central and lateral lymph node extension is increased, nodules located at the upper pole of the thyroid also harbor a higher probability of lateral lymph node extension with an odds ratio of 10 \[[@B42]\]. Future guidelines should also take into account that for nodules measuring \<10 mm and which have suspicious US signs but no signs of local or metastatic invasion, deferring from making the diagnosis of microcarcinoma by FNA and proceeding to US follow-up is an option. This is based on their overall good prognosis as emphasized above.

Supracentimetric Nodules {#sec2_2}
------------------------

The selection of the nodules that should be referred for FNA is based mainly on US risk stratification and on the evolution in size. FNA can be suggested for all nodules scored TIRADS 4B and 4A. For nodules scored TIRADS 3, given the very high negative predictive value of these scores, FNA could be suggested for nodules \>20 mm or in case of verified growth (+2 mm in 2 different axes) and the remainders could be monitored by periodic neck US, e.g. after 1 year initially and then after 2 or 3 years. Complete discharge of the patient could be advised in case the disease is stable.

Translating US Risk Stratification to Individualized Care {#sec1_6}
=========================================================

Independent of the means by which the thyroid incidentaloma is diagnosed, with the exception of a focal uptake on PET-CT, the risk of malignancy is thought to be low and the prognosis excellent. In these patients, overlooking thyroid malignancy, or more correctly postponing the diagnosis of malignancy, with few exceptions, is not likely to influence subsequent type of therapy or the life expectancy of the patient, although at present this remains unclarified \[[@B57],[@B58]\]. Whether benign or malignant, there is no agreement on whether to offer therapy, and recommendations span from observation to total thyroidectomy. It is with this in mind, albeit difficult to maintain when the patient cannot be given a 100% assurance of the lesion being benign, that the management of thyroid incidentalomas should be considered. The available thyroid nodule guidelines give little guidance on how to manage incidentalomas \[[@B59]\]. Therefore, we believe that investigations should be based on risk stratification, including thyroid US and FNA, in order not to overdiagnose and overtreat the patients.

In the end, any decision concerning supplementary investigations and whether to offer therapy, and if so which one, is based on a dialogue between the patient and his/her physician. It follows that the statistical risk is of little help and may not influence the choice made, which is often based on factors that overrule the rationality of algorithms dealing with virtual patients \[[@B48],[@B59],[@B60]\].

Surgical and Nonsurgical Therapy of Thyroid Incidentalomas {#sec1_7}
==========================================================

Undoubtedly, many patients will accept conservative follow-up. However, a number, now burdened with a diagnosis, have become symptomatic and wish therapy. In case of large symptomatic multinodular goiters, the reference treatment remains surgery, total or near-total thyroidectomy, or radioiodine therapy, as dealt with elsewhere \[[@B2],[@B60],[@B61]\]. However, when the incidentaloma (1) has been proven to be benign by at least two US FNAs, (2) is a solitary or dominant nodule and (3) grows, alternative nonsurgical treatment options may be considered. Viewed in this way, and accepting that we have little evidence-based experience in this group of patients, it could be speculated that minimally invasive nonsurgical ablation could become an alternative to surgery and be performed similar to that published for symptomatic benign nodules over the past two decades and recently extensively reviewed \[[@B62],[@B63],[@B64]\]. There are several options, which include percutaneous ethanol injection therapy, interstitial laser photocoagulation and radiofrequency ablation.

Percutaneous Ethanol Injection Therapy {#sec2_3}
--------------------------------------

When used in solid nodules, whether functioning or not, volume is usually reduced by approximately 50-70%, depending on the number of sessions, with a concomitant improvement in symptomatology \[[@B62],[@B63]\]. However, injecting small amounts of absolute ethanol can be painful, rarely leads to total ablation of the nodule, is associated with seepage of ethanol with the potential of causing extrathyroidal fibrosis and other potentially severe side effects, and is probably associated with a considerable recurrence risk \[[@B62],[@B65]\]. For these reasons it has largely been abandoned, with the exception of dominantly cystic thyroid lesions where it performs excellently \[[@B59],[@B66]\]. We have no reason to believe that incidentalomas would respond differently.

Interstitial Laser Photocoagulation {#sec2_4}
-----------------------------------

Increasingly used, and based on long-term follow-up studies, interstitial laser photocoagulation can achieve approximately the same results as percutaneous ethanol injection therapy, but with a more benign side-effect profile due to the ability to contain the energy intranodularly. Also here the best results are seen for cystic nodules \[[@B67]\], both as for remission of the cyst and for reduction of the solid portion. The feasibility and efficacy of ablating small unresectable thyroid malignancies, whether intrathyroidal microcarcinomas \[[@B68]\] or recurrent nodal metastases \[[@B69]\], have been documented in a few patients.

Radiofrequency Ablation {#sec2_5}
-----------------------

In 126 benign nonfunctioning thyroid nodules treated with radiofrequency ablation and followed up more than 3 years, a mean volume reduction of 93.4 ± 11.7% was obtained at final evaluation with an overall recurrence rate of 5.6% and a complication rate of 3.6% \[[@B70]\]. This technique could also be used to treat thyroid incidentalomas.

Other potential ablation techniques, such as microwaves and high-frequency US, have yet to be employed for this purpose.

Conclusions {#sec1_8}
===========

Thyroid incidentalomas are overwhelmingly frequent and specific strategies to reduce the economic and psychological burden to patients and society alike are needed.

All patients with a thyroid incidentaloma, independent of mode of detection, should undergo a dedicated neck US with risk stratification. This can be used to decide which nodules should be offered FNA. However, all algorithms should be used as a supplement to clinical knowledge, and not as a substitute for clinical judgment and common sense. US imaging gives clues to the statistical risk of harboring carcinoma but cannot discern which of these nodules are aggressive and require treatment. Weighing the risks of overdiagnosis in the management of thyroid incidentalomas against the benefits of early discovery of some aggressive carcinomas in a dialogue with the patients is essential. A considerable number of patients with small nodules and no US signs of suspicion do not need medical follow-up.

Surgery and novel nonsurgical ablation techniques may offer the same benefits as in thyroid nodules diagnosed in any other way, but the use of these alternative techniques is not yet evidence-based, especially in the case of malignancy.

Additional studies primarily need to focus on increasing the number of patients who with negligible risk can be discharged from medical care. Unfortunately, we question whether long-term randomized studies focusing on risk of overlooking malignancy, overall cost and quality of life, which would provide the basis of evidence-based care, are feasible.
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###### 

Reported sensitivities and specificities of US characteristics for the presence of malignancy in thyroid nodules

                                        Diagnostic value   Rago et al. \[16\]   Papini et al. \[17\]   Kim et al. \[18\]   Cappelli et al. \[19\]   Moon et al. \[20\]   Russ et al. \[33\]   Trimboli et al. \[22\]   Bojunga et al. \[21\]   Bojunga et al. \[23\]   Zhang et al. \[24\]   Reported range
  ------------------------------------- ------------------ -------------------- ---------------------- ------------------- ------------------------ -------------------- -------------------- ------------------------ ----------------------- ----------------------- --------------------- ----------------
  Cases                                                    104                  402                    155                 6,135                    849                  500                  498                      639                     158                     173                   104 -- 6,135
                                                                                                                                                                                                                                                                                             
  Carcinomas, %                                            29                   8                      30                  5                        42                   3.2                  25                       24                      13                      25                    3 -- 42
                                                                                                                                                                                                                                                                                             
  Study design                                             ?                    P                      P                   R                        R                    R                    P                        meta-analysis           ?                       ?                     
                                                                                                                                                                                                                                                                                             
  Absent halo                           sensitivity        67                                                                                                            87                                                                    90                      91                    67 -- 91
                                        specificity        77                                                                                                            34                                                                    37                      50                    34 -- 77
                                                                                                                                                                                                                                                                                             
  Macrocalcifications                   sensitivity                                                                                                 10                   33                                                                                                                  10 -- 33
                                        specificity                                                                                                 96                   87                                                                                                                  87 -- 96
                                                                                                                                                                                                                                                                                             
  Calcifications (type not specified)   sensitivity                                                                        72                                                                                                                                                                72
                                        specificity                                                                        71                                                                                                                                                                71
                                                                                                                                                                                                                                                                                             
  Microcalcifications                   sensitivity        54                   29                     59                                           44                   38                   31                                               71                      52                    29 -- 71
                                        specificity        76                   95                     86                                           91                   99                   98                                               67                      89                    67 -- 99
                                                                                                                                                                                                                                                                                             
  Hypoechogenicity                      sensitivity        67                   87                                         81                       87                   67                   72                                               62                      98                    67 -- 98
                                        specificity        49                   43                                         47                       58                   87                   60                                               65                      46                    43 -- 87
                                                                                                                                                                                                                                                                                             
  Marked                                sensitivity                                                    27                                           41                   17                                                                                                                  17 -- 41
                                                                                                                                                                                                                                                                                             
  hypoechogenicity                      specificity                                                    94                                           92                   100                                                                                                                 92 -- 100
                                                                                                                                                                                                                                                                                             
  Blurred margins                       sensitivity                             78                                         53                                            41                                                                                                                  41 -- 78
                                        specificity                             85                                         81                                            89                                                                                                                  81 -- 89
                                                                                                                                                                                                                                                                                             
  Irregular margins                     sensitivity                                                    55                                           48                   26                   25                                               52                                            25 -- 55
                                        specificity                                                    83                                           92                   99                   99                                               81                                            81 -- 99
                                                                                                                                                                                                                                                                                             
  Intranodular vascularization          sensitivity        67                   74                                         62                                            41                   37                                               52                      48                    37 -- 74
                                        specificity        49                   81                                         50                                            89                   88                                               73                      57                    49 -- 89
                                                                                                                                                                                                                                                                                             
  Taller than wide                      sensitivity                                                    33                  76                       40                   22                   14                                                                                             14 -- 76
                                        specificity                                                    93                  60                       91                   97                   99                                                                                             60 -- 99
                                                                                                                                                                                                                                                                                             
  High stiffness                        sensitivity                                                                                                                      74                   81                       82 -- 100               48 -- 76                63 -- 75              48 -- 100
                                        specificity                                                                                                                      91                   62                       78 -- 100               72 -- 92                82 -- 88              62 -- 100

Values represent n unless otherwise indicated. R = Retrospective; P = prospective.

###### 

Reported negative (NPV) and positive predictive (PPV) values of US characteristics for the presence of malignancy in thyroid nodules

                                        Diagnostic value   Rago et al. \[16\]   Papini et al. \[17\]   Kim et al. \[18\]   Cappelli et al. \[19\]   Moon et al. \[20\]   Bonavita et al. \[25\]   Russ et al. \[33\]   Trimboli et al. \[22\]   Bojunga et al. \[21\]   Bojunga et al. \[23\]   Zhang et al. \[24\]   Reported range
  ------------------------------------- ------------------ -------------------- ---------------------- ------------------- ------------------------ -------------------- ------------------------ -------------------- ------------------------ ----------------------- ----------------------- --------------------- ----------------
  Cases                                                    104                  402                    155                 6,135                    849                                           500                  498                      639                     158                     173                   104 -- 6,135
                                                                                                                                                                                                                                                                                                                      
  Carcinomas, %                                            29                   8                      30                  5                        42                                            3.2                  25                       24                      13                      25                    3 -- 42
                                                                                                                                                                                                                                                                                                                      
  Study design                                             ?                    P                      P                   R                        R                                             R                    P                        M                       ?                       ?                     
                                                                                                                                                                                                                                                                                                                      
  Absent halo                           PPV                54                                                                                                                                     6                                                                     18                      38                    6 -- 54
                                                                                                                                                                                                                                                                                                                      
  Present halo                          NPV                85                                                                                                            93                       94                                                                                                                  85 -- 94
                                                                                                                                                                                                                                                                                                                      
  Spongiform                            NPV                                                                                                                              98                       95                                                                                                                  95 -- 98
                                                                                                                                                                                                                                                                                                                      
  Macrocalcifications                   PPV                                                                                                         65                                            10                                                                                                                  10 -- 65
                                        NPV                                                                                                                                                                                                                                                                           --
                                                                                                                                                                                                                                                                                                                      
  Calcifications (type not specified)   PPV                                                                                11                                                                                                                                                                                         11
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Microcalcifications                   PPV                56                   33                     80                                           78                                            60                   87                                               25                      62                    25 -- 87
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Isoechogenicity                       NPV                                                                                                                              93                       85                                                                                                                  85 -- 93
                                                                                                                                                                                                                                                                                                                      
  Hypoechogenicity                      PPV                34                   11                                         7                                                                      19                   38                                               21                      52                    7 -- 52
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Marked hypoechogenicity               PPV                                                            68                                           80                                            73                                                                                                                  68 -- 80
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Blurred margins                       PPV                                     30                                         12                                                                     16                                                                                                                  16 -- 30
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Irregular margins                     PPV                                                            80                                           81                                            57                   86                                               30                                            30 -- 86
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  Intranodular vascularization          PPV                                     24                                         6                                                                      16                   52                                               23                      27                    6 -- 52
                                                                                                                                                                                                                                                                                                                      
  Absent central vascularization        NPV                                                            96                                                                94                       97                   81                                                                                             81 -- 96
                                                                                                                                                                                                                                                                                                                      
  Taller than wide                      PPV                                                            75                  8                        77                                            26                   82                                                                                             8 -- 82
                                        NPV                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                      
  High stiffness                        PPV                                                                                                                                                       37                   42                       46 -- 100               38                      59                    37 -- 100
                                                                                                                                                                                                                                                                                                                      
  Low stiffness                         NPV                                                                                                                                                       98                   91                       88 -- 100               93                      90                    88 -- 100

Values represent n unless otherwise indicated. R = Retrospective; P = prospective; M = meta-analysis.
